2023
Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries
Machado P, Schäfer M, Mahil S, Liew J, Gossec L, Dand N, Pfeil A, Strangfeld A, Regierer A, Fautrel B, Alonso C, Saad C, Griffiths C, Lomater C, Miceli-Richard C, Wendling D, Rodriguez D, Wiek D, Mateus E, Sirotich E, Soriano E, Ribeiro F, Omura F, Martins F, Santos H, Dau J, Barker J, Hausmann J, Hyrich K, Gensler L, Silva L, Jacobsohn L, Carmona L, Pinheiro M, Zelaya M, de los Ángeles Severina M, Yates M, Dubreuil M, Gore-Massy M, Romeo N, Haroon N, Sufka P, Grainger R, Hasseli R, Lawson-Tovey S, Bhana S, Pham T, Olofsson T, Bautista-Molano W, Wallace Z, Yiu Z, Yazdany J, Robinson P, Smith C. Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries. Annals Of The Rheumatic Diseases 2023, 82: 698-709. PMID: 36787993, PMCID: PMC10176347, DOI: 10.1136/ard-2022-223499.Peer-Reviewed Original ResearchConceptsSevere COVID-19High disease activityPandemic time periodDisease activityPsoriatic arthritisMale sexAxial spondyloarthritisCOVID-19Multivariable ordinal logistic regressionPoor COVID-19 outcomesOlder ageFuture respiratory pandemicsCOVID-19 severityCOVID-19 outcomesComorbidity burdenGlucocorticoid intakeGlucocorticoid useCancer comorbidityClinical characteristicsCOVID-19 waveRisk stratificationOrdinal logistic regressionReduced oddsSeverity ScaleRespiratory pandemic
2022
Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance
Ugarte-Gil M, Alarcón G, Izadi Z, Duarte-García A, Reátegui-Sokolova C, Clarke A, Wise L, Pons-Estel G, Santos M, Bernatsky S, Ribeiro S, Al Emadi S, Sparks J, Hsu T, Patel N, Gilbert E, Valenzuela-Almada M, Jönsen A, Landolfi G, Fredi M, Goulenok T, Devaux M, Mariette X, Queyrel V, Romão V, Sequeira G, Hasseli R, Hoyer B, Voll R, Specker C, Baez R, Castro-Coello V, Ficco H, Neto E, Ferreira G, Monticielo O, Sirotich E, Liew J, Hausmann J, Sufka P, Grainger R, Bhana S, Costello W, Wallace Z, Jacobsohn L, Taylor T, Ja C, Strangfeld A, Mateus E, Hyrich K, Carmona L, Lawson-Tovey S, Kearsley-Fleet L, Schäfer M, Machado P, Robinson P, Gianfrancesco M, Yazdany J. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. Annals Of The Rheumatic Diseases 2022, 81: 970-978. PMID: 35172961, PMCID: PMC8882632, DOI: 10.1136/annrheumdis-2021-221636.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusCOVID-19 outcomesSevere outcomesDisease activityLupus erythematosusHigher SLE disease activityActive systemic lupus erythematosusMultivariable ordinal logistic regression modelsSevere COVID-19 outcomesPoor COVID-19 outcomesSLE disease activitySex-adjusted modelsMore severe outcomesCOVID-19 severityCOVID-19Logistic regression modelsOrdinal logistic regression modelsPrednisone doseMale sexGlobal RegistryWorse outcomesMultivariable modelCurrent treatmentComorbiditiesOlder age
2021
Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study
Sattui S, Conway R, Putman M, Seet A, Gianfrancesco M, Beins K, Hill C, Liew D, Mackie S, Mehta P, Neill L, Gomez G, Salinas M, Maldonado F, Mariz H, de Sousa Studart S, Araujo N, Knight A, Rozza D, Quartuccio L, Samson M, Bally S, Maria A, Chazerain P, Hasseli R, Müller-Ladner U, Hoyer B, Voll R, Torres R, Luis M, Ribeirio S, Al-Emadi S, Sparks J, Hsu T, D’Silva K, Patel N, Wise L, Gilbert E, Almada M, Duarte-García A, Ugarte-Gil M, Jacobsohn L, Izadi Z, Strangfeld A, Mateus E, Hyrich K, Gossec L, Carmona L, Lawson-Tovey S, Kearsley-Fleet L, Schaefer M, Sirotich E, Hausmann J, Sufka P, Bhana S, Liew J, Grainger R, Machado P, Wallace Z, Yazdany J, Robinson P, Alliance G, Dahou B, Rath E, Piette Y, Devinck M, Maeyaert B, Ribeiro F, Ribeiro S, Pinheiro M, Quintana R, Gómez G, Roberts K, Baez R, Coello V, Salinas M, Maldonado F, Torres A, Alle G, Tanten R, Ficco H, Nieto R, Gobbi C, Tissera Y, Pisoni C, Paula A, Albiero J, Schmid M, Cosatti M, Gamba M, Leandro C, Cusa M, German N, Bellomio V, Takashima L, Pera M, Cogo K, Elkin M, Medina M, Savio V, Tessel I, Alamino R, Werner M, Ornella S, Casalla L, de la Vega M, Severina M, García M, Lucero L, Romeo C, Moyano S, Barbich T, Bertoli A, Baños A, Petruzzelli S, Matellan C, Conti S, Lazaro M, Gil G, Risueño F, Quaglia M, Scafati J, Cuchiaro N, Rebak J, Pineda S, Calvo M, Picco E, Yanzi J, Maid P, Guaglianone D, Morbiducci J, Porta S, Herscovich N, Zamora J, Kisluk B, Menescardi M, Gallo R, Martire M, Maldini C, Goizueta C, de la Vega Fernandez S, Aeschlimann C, Subils G, Ibáñez S, Chassin-Trubert A, Dong L, Cajas L, Barešic M, Anic B, Culo M, Pavelic T, Stranski K, Karanovic B, Vencovsky J, Píchová M, Filkova M, Hamoud H, Vassilopoulos D, Melgar G, So H, Király M, Vojdanian, Balbir-Gurman A, Abutiban F, Zepa J, Bulina I, Bukauskiene L, Zaueta B, Ortiz A, Tehozol E, Vega D, Rosete D, Nares E, Rodriguez-Reyna T, Gabayet M, Alpízar-Rodríguez D, Irazoque F, Jimenez X, Bon L, Zijlstra T, Hoekstra M, Al-Adhoubi N, Salim B, Giraldo E, Salinas A, Ugarte-Gil M, Nowakowski J, Al-Emadi S, Conway R, Flood R, McCarthy G, Felea I, Filipescu I, Rednic S, Groseanu L, Tamas M, Mlynarikova V, Skamlova M, Zlnay M, Miceková D, Capova L, Macejova Z, Štenová E, Raffayova H, Belakova G, Strakova E, Sencarová M, Žlnayová S, Sabová A, Spisakova D, Oetterová M, Lukacova O, Bakosova M, Hocevar A, de la Torre-Rubio N, Sancho J, Coro M, Garcia J, Martin M, Campos J, Puerta J, Yardimci G, Akar S, Icacan O, Çelik S, Vasylets V, Yeoh S, Vandevelde C, Dunt S, Leeder J, Macphie E, Salerno R, Graver C, Williams K, O'Reilly S, Devine K, Tyler J, Warner E, Pilcher J, Patel S, Nikiphorou E, Chadwick L, Jones C, Harrison B, Thornton L, O'Kane D, Fusi L, Low A, Horton S, Jatwani S, Baig S, Bajwa H, Berglund V, Dahle A, Dorman W, Hargrove J, Hilton M, Lebedoff N, Leonard S, Morgan J, Pfeifer E, Skemp A, Wilson J, Wolff A, Cepeda E, D'Silva K, Hsu T, Patel N, Sparks J, Todd D, Wallace Z, Hare D, Calabrese C, Adams C, Khosroshahi A, Kilian A, White D, Winter M, Fields T, Siegel C, Daver N, Harvey M, Kramer N, Lamore C, Hogarty S, Yeter K, Wise L, Siddique F, Ban B, Tanner T, Ruderman E, Davis W, Quinet R, Scopelitis E, Toribio K, Webb-Detiege T, Zakem J, Abbass K, Kepecs G, Miranda L, Guma M, Haikal A, Mody S, Mueller D, Jayatilleke A, Zell J, Bays A, Dao K, Fatemeh E, Parks D, Karp D, Quiceno G. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. The Lancet Rheumatology 2021, 3: e855-e864. PMID: 34778843, PMCID: PMC8570701, DOI: 10.1016/s2665-9913(21)00316-7.Peer-Reviewed Original ResearchPrimary systemic vasculitisCOVID-19 outcomesPoor COVID-19 outcomesNumber of comorbiditiesRetrospective cohort studySystemic vasculitisPolymyalgia rheumaticaSupplemental oxygenDisease activityCohort studyRisk factorsOdds ratioMultivariable ordinal logistic regression analysisSevere COVID-19 outcomesHigh-dose glucocorticoidsLow disease activitySevere disease activityGiant cell arteritisUnmodifiable risk factorsLogistic regression analysisOrdinal logistic regression analysisCOVID-19Eligible patientsGlucocorticoid useMore comorbiditiesOP0006 ASSOCIATIONS OF BASELINE USE OF BIOLOGIC OR TARGETED SYNTHETIC DMARDS WITH COVID-19 SEVERITY IN RHEUMATOID ARTHRITIS: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE
Sparks J, Wallace Z, Seet A, Gianfrancesco M, Izadi Z, Hyrich K, Strangfeld A, Gossec L, Carmona L, Mateus E, Lawson-Tovey S, Trupin L, Rush S, Schmajuk G, Katz P, Jacobsohn L, Al Emadi S, Wise L, Gilbert E, Duarte-Garcia A, Valenzuela-Almada M, Hsu T, D’silva K, Serling-Boyd N, Dieudé P, Nikiphorou E, Kronzer V, Singh N, Ugarte-Gil M, Wallace B, Akpabio A, Thomas R, Bhana S, Costello W, Grainger R, Hausmann J, Liew J, Sirotich E, Sufka P, Robinson P, Machado P, Yazdany J. OP0006 ASSOCIATIONS OF BASELINE USE OF BIOLOGIC OR TARGETED SYNTHETIC DMARDS WITH COVID-19 SEVERITY IN RHEUMATOID ARTHRITIS: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE. Annals Of The Rheumatic Diseases 2021, 80: 2.1-4. DOI: 10.1136/annrheumdis-2021-eular.1632.Peer-Reviewed Original ResearchTumor necrosis factor inhibitorsTNFi usersInterleukin-6 inhibitorsJanus kinase inhibitorsRituximab usersCOVID-19 severityBristol-Myers SquibbRA disease activityGrant/research supportAssociated with greater oddsRheumatoid arthritisCOVID-19 outcomesPoor COVID-19 outcomesGlobal Rheumatology AllianceSynthetic DMARDsCOVID-19 Global Rheumatology AllianceDMARD useDisease activityBristol-MyersJanus kinase inhibitor usePropensity scoreTumor necrosis factor inhibitor useRheumatic diseasesBaseline useOptimal timing of vaccination